Form 4: Director Acquires LMAT Dividend Equivalent Rights

Joseph P. Pellegrino JR, a Director at LEMAITRE VASCULAR INC, reported the acquisition of dividend equivalent rights tied to various equity awards.

Summary

• Joseph P. Pellegrino JR, a Director of LEMAITRE VASCULAR INC (LMAT), reported the acquisition of dividend equivalent rights (DERs).
• The transactions occurred on March 26, 2026, and were filed on March 30, 2026.
• These DERs accrued on previously granted restricted stock unit (RSU) and performance share unit (PSU) awards.
• Each dividend equivalent right is the economic equivalent of one share of LEMAITRE VASCULAR INC common stock.
• The DERs vest proportionately with their underlying RSU and PSU awards.
• Acquired DERs on this date ranged from 1.2077 to 3.244 shares per specific grant.
• Total beneficially owned DERs after these transactions for each specific grant range from 1.2077 to 24.2949 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine disclosure. While not indicative of operational performance, it reflects ongoing equity participation by a director, which generally aligns insider interests with shareholders.

Positives

• Director Joseph P. Pellegrino JR increased his beneficial ownership through the accrual of dividend equivalent rights, indicating continued equity participation.
• The accrual of DERs is a standard component of the compensation structure for equity awards, aligning director interests with shareholders.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on an insider's beneficial ownership changes.

Industry Context

StockSavvy.ai notes that the accrual of dividend equivalent rights is a common practice in executive and director compensation plans, particularly for companies that pay dividends. This mechanism helps align the interests of insiders with those of common shareholders by ensuring that equity award holders benefit from dividends as if they held the underlying shares, even before vesting.

Comparison to Industry Standards

• This type of insider transaction, involving the accrual of dividend equivalent rights on unvested equity awards, is standard practice across many industries, particularly in companies that utilize restricted stock units (RSUs) and performance share units (PSUs) as part of their long-term incentive compensation.
• Companies like Medtronic (MDT) or Boston Scientific (BSX) in the medical device sector often employ similar equity compensation structures for their executives and directors, where DERs accrue to maintain the economic value of the awards relative to dividend-paying common stock.

Stakeholder Impact

• Shareholders: Minimal direct impact, as this is a routine insider transaction related to compensation. It reinforces alignment of director interests with shareholders through equity participation.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The acquired dividend equivalent rights will vest proportionately with their underlying restricted stock unit and performance share unit awards.

Key Dates

Keywords

LEMAITRE VASCULAR, LMAT, Form 4, Insider Transaction, Beneficial Ownership, Dividend Equivalent Rights, Director, Equity Awards, Restricted Stock Units, Performance Share Units